Pembrolizumab improved progression-free survival (PFS) and overall survival (OS) over best supportive care in patients with advanced hepatocellular carcinoma (HCC), according to the phase III KEYNOTE-240* trial, supporting its role as a treatment option for HCC in the second-line setting.
Exposure to antitumour necrosis factor (anti-TNF) for inflammatory bowel disease also confers benefits for the risk of acute arterial events, especially in men with Crohn’s disease (CD), as shown in a recent study.
A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.
The consent process may help reduce anxiety of patients undergoing colonoscopy, according to a recent study. However, written or video educational adjuncts provided on the day of colonoscopy appear to have no effect on patient perceptions when used in conjunction with a high-quality verbal consent.
Diabetic patients with hepatitis C virus (HCV) may benefit from direct-acting antiviral agents, with a significant portion of patients having a clinically significant reduction in glycated haemoglobin (HbA1c), suggests a recent study. This effect has been sustained among responders over 1.5 years of follow-up.
Among patients with ulcerative colitis, smokers and never-smokers have similar outcomes in terms of flares, thiopurine use, corticosteroid dependency, hospitalization and colectomy, a study reports. Furthermore, while smoking cessation is not associated with worse disease course, the risks associated with tobacco use outweigh any benefits.
The poloxamer-based, temperature-sensitive, anti-adhesive agent Guardix-SG was effective and safe in the prevention of intra-abdominal adhesions and small bowel obstruction in gastric cancer patients after undergoing radical gastrectomy, a Korean study has shown.
Individuals with type 2 diabetes mellitus (T2D) may be at risk of developing gastric cancer even after receiving Helicobacter pylori (H. pylori) eradication therapy, demonstrated a study from Hong Kong.